echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Industry | assisted reproductive services: a hundred billion market you can't know

    Industry | assisted reproductive services: a hundred billion market you can't know

    • Last Update: 2019-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 25, 2019, Jinxin reproductive, known as "the first non-public assisted reproductive stock in China", was listed in Hong Kong and received extensive attention from the market Assisted reproduction, a slightly shy topic involving human morality and ethics, is not often mentioned However, through the data disclosed by Jinxin reproductive, we can find that this is indeed an area with strong market demand and rapid growth Today, we're going to talk to you about this one hundred billion market you can't help but know - assisted reproductive services Infertility is a disease of the reproductive system, which means that after 12 months or more of regular sex without contraception, there is still no clinical pregnancy Globally, infertility is becoming more and more common for many reasons, including the increase of the average age of first-time childbearing, unhealthy lifestyle, environmental factors and so on The causes of female infertility include ovulation, damage of fallopian tube or uterus, and abnormal cervix; the causes of male infertility include insufficient sperm, abnormal sperm function and blocked sperm delivery It is estimated that the global prevalence of infertility will rise from 11.0% in 1997 to 15.4% in 2018, and it is expected to rise to 17.2% by 2023; in China, the prevalence of infertility is expected to increase from 16.0% in 2018 to 18.2% in 2023 At present, the treatment of infertility mainly includes drug treatment, surgical treatment and assisted reproductive technology Assisted reproductive technology includes artificial insemination, gamete transplantation and in vitro baby, in which in vitro baby is the main choice with the highest pregnancy rate There are three generations of IVF-ET, ISCI and PGD / PGs In recent years, with the liberalization of the two child policy and the increase of the prevalence of infertility and other factors, the market of assisted reproduction in China has developed rapidly, and the relevant industrial chain has been gradually improved, from the upstream suppliers of assisted reproductive drugs, testing reagents, equipment, etc., to the Internet service platform of related services in the midstream, and finally to the downstream institutions of assisted reproductive services In the structure of the whole industrial chain, the service institutions of downstream assisted reproduction are always in the core position According to Frost & Sullivan's calculation, the global market of assisted reproductive services increased from US $20.4 billion in 2014 to US $24.8 billion in 2018, with a compound annual growth rate of 5.1% It is expected that it will further increase to US $31.7 billion in 2023 China's market for assisted reproductive services is growing more rapidly, from 14 billion yuan in 2014 to 25.2 billion yuan in 2018, with a compound annual growth rate of 15.8%, which is expected to grow to 49.6 billion yuan in 2023 The high growth in China is mainly due to the improvement of the penetration rate of assisted reproductive services, patients' demand and affordability At present, the stock space of the domestic market exceeds 500 billion yuan Test tube babies need two cycles on average, and the treatment cost of each cycle is about 40000-60000 yuan; artificial insemination needs three cycles on average, and the treatment cost of each cycle is about 5000 yuan At present, the penetration rate of assisted reproductive technology in China is still very low More than 2 million people may be treated by artificial insemination in the future, and more than 5 million people may be treated by in vitro baby in the future At present, the existing stock space of assisted reproductive services in China is more than 500 billion yuan At present, public hospitals are the main medical institutions for assisted reproduction in China 90% of the existing licensed medical institutions for assisted reproduction are public institutions, such as the Third Hospital of Peking University, the Ninth People's Hospital Affiliated to Shanghai Jiaotong University Medical College, and the reproductive Hospital Affiliated to Shandong University The non-public assisted reproductive institutions mainly include CITIC Xiangya reproductive and genetic hospital (state-owned non-public), Jinxin reproductive medical group, Aviv medical group, etc However, from the perspective of IVF egg retrieval cycle, the domestic market for assisted reproductive services is still relatively fragmented: in 2018, the top 10 and 20 providers accounted for 26% and 36% of the market share respectively The advantage of public medical institutions is that the pregnancy rate is generally high and the charges are relatively low; the disadvantage is that the number of patients in line is large and they can not be treated in time Generally, tube baby treatment in local maternal and child health care hospital needs to wait at least half a year The development of assisted reproductive institutions is closely related to the level of local economic development, mainly distributed in East China, accounting for 31.26%, followed by South China, central China and North China, accounting for 18.4%, 16.41% and 15.96% respectively According to the principle of total population / institutions, the average market development density of the country is about 3.08 million people / institution, slightly higher than the principle of "one institution for every 3 million population" proposed in the guiding principles of human assisted reproductive technology allocation planning (2015 Edition); the market development density of Beijing is the highest, about 1.28 million people / institution, and that of Sichuan is the lowest, about 8.3 million people / institution Since assisted reproductive technology involves national policy, ethics and other aspects, strict supervision has always been the main tone At present, the approval system is adopted for assisted reproductive technology in China Although in recent years, due to the increase of market demand for assisted reproductive technology and the progress of assisted reproductive technology, national supervision has been relaxed While emphasizing quality standards and technical specifications, provinces have welcomed the release of assisted reproductive technology The approval of the center is still relatively strict on the whole Therefore, IVF license is one of the core values of the whole assisted reproductive system Test tube baby technology has higher requirements for doctors and equipment in medical institutions The level of test tube baby technology determines the pregnancy rate of patients, and successful pregnancy is an important prerequisite for establishing the reputation of the assisted reproductive industry, which will greatly enhance the competitiveness and market value of medical institutions Therefore, the ability to access doctors' resources, especially domain experts' resources, and the high pregnancy rate of patients are also the core competitiveness of the assisted reproductive industry 1 Jinxin reproductive medical group Jinxin reproductive medical group is a leading provider of assisted reproductive services in China and the United States Its three centers include Chengdu Xinan, Shenzhen Zhongshan and the United States HRC fertility The group's history can be traced back to 2003, when a team of senior and dedicated doctors and managers established Jinjiang IVF center in Chengdu, Sichuan Province, focusing on assisted reproductive services and related treatment In 2017, the Group acquired Shenzhen Zhongshan Hospital, which was established by several individual founders in May 2004 Shenzhen Zhongshan Hospital provides assisted reproduction and other auxiliary medical services, and assists Shenzhen in the birth of the first baby through ive-et technology and IVF in cooperation with ICSI technology In 2019, the Group acquired hrcmanagement in the United States, enhancing its ability to provide high-value assisted reproductive services for international patients, especially those from China Hrcfertility is a leading provider of assisted reproductive services in the United States with over 30 years of experience 2 Aviev medical group Aviev medical group is a professional medical supplier with test tube baby as the core, covering the upstream and downstream, including obstetrics and Gynecology, baby care, post natal rehabilitation and high-end pediatrics In 2001, it was established under the personal guidance and care of Professor Zhang Lizhu, the mother of test tube babies in Shenzhou At present, the group has completed more than 15000 IVF cycles and more than 50000 IVF births The group has many independent or cooperative medical entities, such as Shenzhen Aiwei Aifu gynecological hospital, Tianjin Aiwei hospital, Zhanjiang Jiuhe hospital, Jieyang Aiwei Aifu hospital, Kunming Aiwei Aifu hospital.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.